- Blog
Risk Mitigation in Clinical Trials: Centralized Procurement for Global Decentralized Trials
5 Minutes
November 14, 2023
Last updated: August 14, 2026
The risks associated with decentralized procurement and how to prioritize risk mitigation in clinical trials.
Global Decentralized Clinical Trials (DCTs) have transformed medical research by improving patient access, expanding participant diversity, and accelerating recruitment timelines. However, managing supply chains across scattered trial sites creates severe logistical vulnerabilities. Without a centralized procurement strategy, sponsors and contract research organizations (CROs), risk budget overruns, compliance breaches, and trial delays.
Centralized procurement serves as a core framework for risk mitigation in clinical trials, ensuring regulatory alignment, product integrity, and seamless delivery to sites and patients worldwide.
What is Centralized Procurement in Decentralized Clinical Trials?
Centralized procurement in DCTs is the single-source management, sourcing, and distribution of investigational medicinal products (IMPs), ancillary supplies, and medical equipment across all trial locations. Rather than allowing individual trial sites to source items independently, a centralized model standardizes vendor negotiations, quality control, regulatory approvals, and global logistics under one operational strategy.
The Hidden Risks of Decentralized Procurement
Allowing trial sites to independently procure supplies introduces systemic failure points across global studies. Industry data suggest that up to 95% of phase three trials already use at least one element of decentralization. Overlooking risk mitigation in clinical trials includes the following:
Inflated operational costs:
Sourcing supplies on a site-by-site basis leads to redundant contracting, lost bulk-purchasing discounts, and varied pricing structures that quickly inflate budgets.
Inconsistent material quality:
Decentralized sourcing creates variability in supply quality, storage standards, and availability across regions, threatening the requirement for uniform trial protocols.
Costly shipment delays:
Independent procurement increases exposure to import bottlenecks and customs holds, directly delaying participant dosing and study timelines.
Regulatory and import bottlenecks:
Navigating country-specific import laws, health authority approvals, and customs procedures without centralized expertise significantly increases non-compliance risks.
Dosing and supply errors:
Fragmented tracking across multiple vendors increases the risk of stockouts, expired inventory, or administration errors.
Ethical and diversion violations:
Uncentralized supply chains lack end-to-end visibility, increasing the risk of unauthorized product diversion, inventory loss, or non-compliance with local health authority mandates.
Core Benefits of Centralized Procurement and How it Mitigates Risk
| Category | Uncentralized Procurement | Centralized Solution |
|---|---|---|
| Vendor Management | Multiple contracts, variable pricing | Single vendor network, standardized pricing |
| Supply Consistency | Varied equipment and batch quality | Uniform, high-quality supplies across all sites |
| Customs & Compliance | High risk of stuck shipments | Single medical IOR handling global import compliance |
| Supply Chain Visibility | Fragmented, site-level tracking | Real-time, end-to-end digital tracking |
| Cost Control | Redundant fees and markup costs | Consolidated purchasing and optimized freight spend |
Strategic Steps for Risk Mitigation in Clinical Trials in DCT Supply Chains
To maximize efficiency and safeguard global studies, sponsors and CROs should implement three advanced procurement and logistics strategies:
Partnering with a Medical IOR for Seamless DCT Logistics
Centralizing procurement is only half the equation; cross-border delivery requires rigorous compliance management. When conducting global DCTs, sponsors often lack local legal entities in destination countries.
As a specialized medical Importer of Record (IOR), TecEx Medical acts as the authorized entity responsible for navigating local health regulations, managing customs clearance, paying duties and taxes, reclaiming VAT, and ensuring end-to-end Good Distribution Practice (GDP) compliance. By pairing centralized procurement with an experienced Medical IOR, pharmaceutical sponsors eliminate regulatory bottlenecks and ensure robust risk mitigation for Clinical Trials.
Drive Efficiency in Your Global Trials
Don’t let supply chain complexities compromise your research and ability to mitigate risk for your clinical trial. Partner with TecEx Medical to streamline your procurement, ensure regulatory compliance, and execute seamless decentralized clinical trials globally.
